Recardio Announces Expansion of Series C Financing and Initial Closing of Series C+ Round

San Francisco, May 6, 2026 - Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced the expansion of its Series C financing and the initial close of its Series C+ financing round.

Recardio Announces Expansion of Series C Financing and Initial Closing of Series C+ Round

This financing includes participation from existing shareholders as well as new undisclosed investors. Proceeds from the Series C+ round will supplement the existing Series C financing and support the expansion of the Recardio’s therapeutic pipeline into additional cardiometabolic assets in clinical and preclinical development.

Recardio’s multiple disease-modifying and regenerative therapeutic approaches have the potential to significantly improve survival rates and quality of life for patients suffering from acute and chronic cardiometabolic diseases.

About Recardio

Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.

The company is located in San Francisco, California, with operations in the USA and Europe.

Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.

In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.

For more information, visit: http://www.recardio.eu/  or contact pr@recardio.eu